Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development

Research output: Contribution to journalReviewpeer-review

Standard

Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy : a novel strategy in drug development. / Stenvang, Jan; Kümler, Iben; Nygård, Sune Boris; Smith, David Hersi; Nielsen, Dorte; Brünner, Nils; Moreira, José.

In: Frontiers in Oncology, Vol. 3, 313, 2013.

Research output: Contribution to journalReviewpeer-review

Harvard

Stenvang, J, Kümler, I, Nygård, SB, Smith, DH, Nielsen, D, Brünner, N & Moreira, J 2013, 'Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development', Frontiers in Oncology, vol. 3, 313. https://doi.org/10.3389/fonc.2013.00313

APA

Stenvang, J., Kümler, I., Nygård, S. B., Smith, D. H., Nielsen, D., Brünner, N., & Moreira, J. (2013). Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development. Frontiers in Oncology, 3, [313]. https://doi.org/10.3389/fonc.2013.00313

Vancouver

Stenvang J, Kümler I, Nygård SB, Smith DH, Nielsen D, Brünner N et al. Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development. Frontiers in Oncology. 2013;3. 313. https://doi.org/10.3389/fonc.2013.00313

Author

Stenvang, Jan ; Kümler, Iben ; Nygård, Sune Boris ; Smith, David Hersi ; Nielsen, Dorte ; Brünner, Nils ; Moreira, José. / Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy : a novel strategy in drug development. In: Frontiers in Oncology. 2013 ; Vol. 3.

Bibtex

@article{86d5e2ad485540dca80bc75a6863371c,
title = "Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development",
abstract = "Cancer is a leading cause of mortality worldwide and matters are only set to worsen as its incidence continues to rise. Traditional approaches to combat cancer include improved prevention, early diagnosis, optimized surgery, development of novel drugs, and honing regimens of existing anti-cancer drugs. Although discovery and development of novel and effective anti-cancer drugs is a major research area, it is well known that oncology drug development is a lengthy process, extremely costly and with high attrition rates. Furthermore, those drugs that do make it through the drug development mill are often quite expensive, laden with severe side-effects and unfortunately, to date, have only demonstrated minimal increases in overall survival. Therefore, a strong interest has emerged to identify approved non-cancer drugs that possess anti-cancer activity, thus shortcutting the development process. This research strategy is commonly known as drug repurposing or drug repositioning and provides a faster path to the clinics. We have developed and implemented a modification of the standard drug repurposing strategy that we review here; rather than investigating target-promiscuous non-cancer drugs for possible anti-cancer activity, we focus on the discovery of novel cancer indications for already approved chemotherapeutic anti-cancer drugs. Clinical implementation of this strategy is normally commenced at clinical phase II trials and includes pre-treated patients. As the response rates to any non-standard chemotherapeutic drug will be relatively low in such a patient cohort it is a pre-requisite that such testing is based on predictive biomarkers. This review describes our strategy of biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy, taking the repurposing of topoisomerase I (Top1) inhibitors and Top1 as a potential predictive biomarker as case in point.",
author = "Jan Stenvang and Iben K{\"u}mler and Nyg{\aa}rd, {Sune Boris} and Smith, {David Hersi} and Dorte Nielsen and Nils Br{\"u}nner and Jos{\'e} Moreira",
year = "2013",
doi = "10.3389/fonc.2013.00313",
language = "English",
volume = "3",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S.A.",

}

RIS

TY - JOUR

T1 - Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy

T2 - a novel strategy in drug development

AU - Stenvang, Jan

AU - Kümler, Iben

AU - Nygård, Sune Boris

AU - Smith, David Hersi

AU - Nielsen, Dorte

AU - Brünner, Nils

AU - Moreira, José

PY - 2013

Y1 - 2013

N2 - Cancer is a leading cause of mortality worldwide and matters are only set to worsen as its incidence continues to rise. Traditional approaches to combat cancer include improved prevention, early diagnosis, optimized surgery, development of novel drugs, and honing regimens of existing anti-cancer drugs. Although discovery and development of novel and effective anti-cancer drugs is a major research area, it is well known that oncology drug development is a lengthy process, extremely costly and with high attrition rates. Furthermore, those drugs that do make it through the drug development mill are often quite expensive, laden with severe side-effects and unfortunately, to date, have only demonstrated minimal increases in overall survival. Therefore, a strong interest has emerged to identify approved non-cancer drugs that possess anti-cancer activity, thus shortcutting the development process. This research strategy is commonly known as drug repurposing or drug repositioning and provides a faster path to the clinics. We have developed and implemented a modification of the standard drug repurposing strategy that we review here; rather than investigating target-promiscuous non-cancer drugs for possible anti-cancer activity, we focus on the discovery of novel cancer indications for already approved chemotherapeutic anti-cancer drugs. Clinical implementation of this strategy is normally commenced at clinical phase II trials and includes pre-treated patients. As the response rates to any non-standard chemotherapeutic drug will be relatively low in such a patient cohort it is a pre-requisite that such testing is based on predictive biomarkers. This review describes our strategy of biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy, taking the repurposing of topoisomerase I (Top1) inhibitors and Top1 as a potential predictive biomarker as case in point.

AB - Cancer is a leading cause of mortality worldwide and matters are only set to worsen as its incidence continues to rise. Traditional approaches to combat cancer include improved prevention, early diagnosis, optimized surgery, development of novel drugs, and honing regimens of existing anti-cancer drugs. Although discovery and development of novel and effective anti-cancer drugs is a major research area, it is well known that oncology drug development is a lengthy process, extremely costly and with high attrition rates. Furthermore, those drugs that do make it through the drug development mill are often quite expensive, laden with severe side-effects and unfortunately, to date, have only demonstrated minimal increases in overall survival. Therefore, a strong interest has emerged to identify approved non-cancer drugs that possess anti-cancer activity, thus shortcutting the development process. This research strategy is commonly known as drug repurposing or drug repositioning and provides a faster path to the clinics. We have developed and implemented a modification of the standard drug repurposing strategy that we review here; rather than investigating target-promiscuous non-cancer drugs for possible anti-cancer activity, we focus on the discovery of novel cancer indications for already approved chemotherapeutic anti-cancer drugs. Clinical implementation of this strategy is normally commenced at clinical phase II trials and includes pre-treated patients. As the response rates to any non-standard chemotherapeutic drug will be relatively low in such a patient cohort it is a pre-requisite that such testing is based on predictive biomarkers. This review describes our strategy of biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy, taking the repurposing of topoisomerase I (Top1) inhibitors and Top1 as a potential predictive biomarker as case in point.

U2 - 10.3389/fonc.2013.00313

DO - 10.3389/fonc.2013.00313

M3 - Review

C2 - 24400218

VL - 3

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - 313

ER -

ID: 98037812